NATIONAL INSTITUTES OF HEALTH
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Adult L1 Acute Lymphoblastic LeukemiaAdult L2 Acute Lymphoblastic LeukemiaAdult T Acute Lymphoblastic LeukemiaRecurrent Adult Acute Lymphoblastic Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationOther: Laboratory Biomarker AnalysisProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 97
- Registration Number
- NCT00792948
- Locations
- πΊπΈ
Banner University Medical Center - Tucson, Tucson, Arizona, United States
πΊπΈUniversity of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
Community Cancer Centers Pilot Patient Survey
- Conditions
- CancerMalignant Neoplasms
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3955
- Registration Number
- NCT00786656
- Locations
- πΊπΈ
Research Triangle Institute International, Research Triangle Park, North Carolina, United States
EZIO Compared to Central Venous Lines for Emergency Vascular Access
- Conditions
- Catheters, IndwellingCentral Venous LineIntraosseous Needle
- Interventions
- Device: standard central lineDevice: Powered Intraosseous device (EZIO)
- Locations
- πΊπΈ
Dept of Emergency Medicine, The George Washington University Medical Center, Washington, District of Columbia, United States
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
- Conditions
- Estrogen Receptor NegativeHER2/Neu PositiveProgesterone Receptor PositiveProgesterone Receptor NegativeRecurrent Breast CarcinomaStage IIIC Breast Cancer AJCC v6Estrogen Receptor PositiveHER2/Neu NegativeStage IV Breast Cancer AJCC v6 and v7
- Interventions
- Biological: BevacizumabOther: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2022-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 799
- Registration Number
- NCT00785291
- Locations
- πΊπΈ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
πΊπΈSparks Regional Medical Center, Fort Smith, Arkansas, United States
πΊπΈMercy Hospital Fort Smith, Fort Smith, Arkansas, United States
Diindolylmethane in Preventing Cancer in Healthy Volunteers
- Conditions
- Healthy, no Evidence of Disease
- Interventions
- Other: placeboOther: pharmacological studyOther: laboratory biomarker analysisOther: quality-of-life assessment
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00784394
- Locations
- πΊπΈ
University of Kansas Medical Center, Kansas City, Kansas, United States
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
- Conditions
- Squamous Lung DysplasiaNon-small Cell Lung Cancer
- Interventions
- Other: placebo
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 85
- Registration Number
- NCT00783705
- Locations
- πΊπΈ
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
πΊπΈMayo Clinic, Rochester, Minnesota, United States
πΊπΈAlbuquerque Veterans Administration Medical Center, Albuquerque, New Mexico, United States
IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery
- Conditions
- Recurrent Adrenocortical CarcinomaStage III Adrenocortical CarcinomaStage IV Adrenocortical Carcinoma
- Interventions
- Biological: IMC-A12
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00778817
- Locations
- πΊπΈ
University of Southern California, Los Angeles, California, United States
πΊπΈUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
πΊπΈDecatur Memorial Hospital, Decatur, Illinois, United States
Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Recurrent Non-small Cell Lung CancerStage IIIA Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00778167
- Locations
- πΊπΈ
University of Colorado, Denver, Colorado, United States
πΊπΈRoswell Park Cancer Institute, Buffalo, New York, United States
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
- Conditions
- Bladder Cancer
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00776178
- Locations
- πΊπΈ
National Cancer Institute (NCI), 9000 Rockville Pike, Bethesda, Maryland, United States
18F- Fluorothymidine to Evaluate Treatment Response in Lymphoma
- Conditions
- Lymphoma
- Interventions
- Procedure: BiopsyDiagnostic Test: fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomographyOther: [3'-deoxy-3'-[F-18] fluorothymidineProcedure: computed tomographyProcedure: fine-needle aspiration
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00775268
- Locations
- πΊπΈ
Walter Reed National Medical Center, Bethesda, Maryland, United States
πΊπΈNational Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States